4754 Investors following Pfizer. Share this News with them.
0
Like this story, share it with millions of investors on M3
Pfizer's aim to replace Lipitor looks difficult
Pfizer's aim to replace Lipitor before its patent expires is looking rather difficult as their new heart medication drug has shown serious side effects in clinical trials. CNBC-TV18 reports on what sort of an upside it provides to Ranbaxy.
Pfizer 's aim to replace Lipitor before its patent expires looks rather difficult as their new heart medication drug has shown serious side effects in clinical trials. CNBC-TV18 reports on what sort of an upside it provides to Ranbaxy .
Pfizer will be losing patents on Lipitor from 2010. Thinking that it will have to recoup that kind of a loss, it was working on Torcetrapib, which was a very potent cholesterol reducing agent. Now because Torcetrapib has not shown the right reaction, it has actually gone into problems with the US FDA.
Lipitor will have to be promoted by Pfizer and that will mean that one can expect the sales of Lipitor to continue to rise. So Ranbaxy will be able to make more money because people had already started thinking that Lipitor has reached its peak in global sales.
Ranbaxy may launch generic Lipitor in 2010 and has exclusivity for the drug. When the patent really expires, Ranbaxy can expect good sales from the same product and Lipitor will probably continue to be a top selling product on the whole.
Basically, Pfizer is not a company, which will give up very easily. It is still saying that it will work on a better model. But overall, from what CNBC-TV18 understands from media reports and analysts is that it has been seen as a big blow for Pfizer and to replace a portal blockbuster will be quite difficult for Pfizer now.
Pfizer will be losing patents on Lipitor from 2010. Thinking that it will have to recoup that kind of a loss, it was working on Torcetrapib, which was a very potent cholesterol reducing agent. Now because Torcetrapib has not shown the right reaction, it has actually gone into problems with the US FDA. 
